



Hot flushes, sweating



Irritability, anxiety, depression



Endometrial hyperplasia

Below the surface of the climacteric




Dry vagina



Osteoporosis
(affects one
patient
in three!)



Irregular periods



Cyclo-Progynova

The all-round treatment for menopausal problems

1. *Modern Medicine* 45, 10, 1977 **Presentation** Circular memo-pack holding 11 white tablets each containing 2mg oestradiol valerate and 10 orange tablets each containing 2mg oestradiol valerate and 0.5mg norgestrel. All tablets are sugar-coated with 'B' in a regular hexagon printed on each side. **Uses** i) The alleviation of symptoms characteristic of the menopause. Cyclo-Progynova may be used both before and after the menopause. ii) The correction of irregularities of the menstrual cycle caused by abnormal oestrogen production and diminishing corpus luteum function as the menopause approaches. **N.B.** Cyclo-Progynova should not be used as an oral contraceptive. **Dosages and administration** Patients still having periods may start tablet-taking on the fifth day of the cycle, counting the first day of bleeding as day one. Patients whose periods are very irregular or non-existent may start taking the tablets at any time. The memo-pack sticker should be attached so that the starting day is correctly indicated in the red section. One white tablet is taken daily for eleven days, followed by one orange tablet daily for ten days. An interval of seven days follows each pack, during which bleeding will normally occur. **Contra-indications** Severe disturbances of liver function, jaundice or persistent itching during a previous pregnancy. **Dubin-Johnson syndrome.** Rotor syndrome, existing or previous thromboembolic processes (including strokes), sickle-cell anaemia, existing or treated cancer of the breast or endometrium, endometriosis, mastopathy, myomatous uterus, congenital disturbances of lipid metabolism, a history of herpes of pregnancy, otosclerosis with deterioration in previous pregnancies. **Warnings/Side effects** Use with caution in patients who have a history of congenital abnormalities of lipid metabolism. Some women are predisposed to cholestasis during steroid therapy. Uterine fibroids may be affected by oestrogens and should be checked frequently. **Note:** Treatment should be stopped at once if jaundice or pregnancy occurs or if advised for patients receiving long-term treatment with Cyclo-Progynova. In patients with chronic liver disease, liver function tests should be checked frequently. **Overdosage** Toxic effects of overdosage have not been reported, but, if desired, with an oral contraceptive is not recommended. **Shering** There is a significant rise in blood pressure. **Precautions and special information** Periodical gynaecological examinations are should be checked every 8-12 weeks. Irregular bleeding during tablet-taking should be investigated. The use of Cyclo-Progynova gastric lavage can safely be used. There are no special antidotes, and further treatment should be symptomatic. **Legal category** POM. **Basic NHS price** £2.24. **Product licence number** 0053/0053. Further information on Cyclo-Progynova is available on request. **Schering Chemicals Limited, Pharmaceutical Division, Burgess Hill, West Sussex RH15 9NE.**


Reflux oesophagitis

the role of gastric acid

Number 1
in a series

Healing

By its fundamental action in reducing both acidity and volume of gastric juice,¹ 'Tagamet' has been shown to achieve complete healing or marked improvement in the majority of patients with reflux oesophagitis.^{2,3} Overall experience in clinical trials² has shown that, at the recommended dosage, 62% of 39 patients had complete healing or marked improvement compared with only 9% of 23 patients on placebo. Complete resolution of stricture, ulcers and erosions was also demonstrated in individual patients.



Symptomatic Relief

In one study¹ most patients obtained rapid symptomatic improvement during 'Tagamet' treatment and within 4 weeks many were free from symptoms. A considerable reduction in the incidence of heartburn, reflux, dysphagia and odynophagia was also observed during therapy.

(Artist's impression of H₂ receptor antagonist acting on receptor site in the parietal cell in gastric mucosa.)

reduces gastric acid
secretion

References

1. Pharmacological evaluation of cimetidine, a new Histamine H₂-Receptor Antagonist. (1975) Brit. J. clin. Pharmacol., 2, 481.
2. Data on file (March 1977) Smith Kline & French.

3. Cimetidine in the treatment of oesophagitis. (1977) Proceedings of the Second International Symposium on Histamine H₂-Receptor Antagonists. Excerpta Medica, p. 297.

'Tagamet' (cimetidine) is available as 200mg film-coated tablets, 200mg/5ml syrup and 200mg/2ml ampoules.

SK&F
a SmithKline company

Full prescribing information is available from:-
Smith Kline & French Laboratories Limited
Welwyn Garden City
Hertfordshire AL7 1EY
Telephone: Welwyn Garden 25111
'Tagamet' is a trade mark.

TG:AD18



Amoxil success everyday

Otitis media

Amoxil is quoted as 'the treatment of choice' in otitis media in children under five in a recent expert review in the Practitioner.¹

Bronchitis

"In my opinion, the most straightforward treatment of this condition, in patients not allergic to penicillin, is amoxycillin... taken at the first sign of increasing sputum purulence."¹

Other respiratory infections

In various upper and lower respiratory infections, Amoxil has been shown to achieve 84% response within three days of the commencement of treatment in 243 children studied.²

References 1. Practitioner (1977) **219**, 449-455. 2. Brit. J. Clin. Pract. (1975), **29**, (8), 203.

Further information on Amoxil (regd.) amoxycillin is available on request to the company. Bencard, Great West Road, Brentford, Middx.

 **Bencard**

For your elderly and bronchitic patients the outlook is not so pleasant

Every autumn it's your patients with respiratory disease who look ahead with the most foreboding.

The elderly and those living in closed communities are also specially vulnerable.

Protect them this winter – vaccinating with Fluvirin.

Fluvirin offers the following considerable advantages:

- The highest degree of purity yet obtainable
- A positive protection rate up to 90% of vaccinated patients
- A full immunising dose of the recommended strains
- A much reduced risk of adverse systemic reactions.
- British made; likely to be available even when imported vaccines are not
- The most positive practical step you can take in the control of influenza and so ease your winter work-load

Fluvirin is a highly purified adsorbed surface antigen influenza vaccine. It is made by an advanced process which reduces viral protein to one tenth of that found in conventional vaccines.

A vaccine prepared in this way has been described as **the ultimate in purified antigens**

(Br. med. J., 1975, 1, 508).

Each 0.5ml dose contains the haemagglutinin and neuraminidase antigens prepared from:
200 Units of A/USSR/92/77 (H₁N₁)
200 Units of A/England/321/77 (H₃N₂)
200 Units of B/Hong Kong/8/73
adsorbed onto aluminium hydroxide.

Plan your immunisation programme for them now with

FLUVIRIN

The advanced British influenza vaccine.

Prescribing Information: **Presentation:** Fluvirin, adsorbed surface antigen influenza vaccine, contains, in 0.5ml dose, the strains of influenza virus currently recommended. **Uses:** Protection against influenza. **Dosage:** Adults and children over the age of 9: 0.5ml, by deep subcutaneous or intramuscular injection; for those under 23, two doses of 0.5ml, at one month apart. **Warnings:** Contra-indicated in persons sensitive to egg protein. The potential risk of adverse reaction to vaccines should be taken into account in patients with a personal or family history of allergy. Spirit should not be allowed to come in contact with the vaccine. **Side-effects:** Redness and soreness at the site of injection, headache, pyrexia and a feeling of malaise may occur. **Package quantities:** Single dose ampoules of 0.5ml at a basic NHS cost of £1.70, and multidose vials of 5ml. PL0021/0063.



Fluvirin is a Trade Mark of Duncan, Flockhart & Co Limited, London, E2 6LA. Full information is available on request.

DF 78/12B/HN

Talpen the routine antibiotic that won't upset your patients' routine

Effective Your main consideration is to help your patient to get better quickly. Talpen is highly effective across a wide range of indications. For example, a published clinical trial produced a 93.0% success in bronchitis; a 94.3% success in UTI; and a 95.6% success in ENT.¹


Easy To Take Just one Talpen tablet three times a day. And Talpen's reliable absorption means it can be taken with or without food.² So your patients find it easy to remember and are more likely to take the full prescribed course of treatment.

Furthermore, Talpen is very well tolerated.^{1,3} (The incidence of diarrhoea, for example, is only 4%.¹) So your patients can carry on their normal daily routine.

Economical Talpen is effective, reliable, easy to take – and it's economical at an average daily cost of 26p.⁴

Talpen

Everything your routine antibiotic should be



Prescribing Information. Typical indications include: Acute and Chronic Bronchitis, Pneumonia, ENT infections, UTI. Usual Oral Dosage: Adults: 1 tablet three times a day. Each tablet contains 250 mg of the ampicillin ester, talampicillin hydrochloride equivalent to 169 mg of ampicillin. Contra-indication: Penicillin hypersensitivity. Precaution: Talpen is not recommended for patients with severe renal or hepatic impairment. Side-effects: As with other penicillins. An erythematous rash may occasionally occur. The incidence is particularly high in patients with infectious mononucleosis. Further information is available on request to the company. 1. Br. J. Clin. Pract., (1975), **29**, 255. 2. Brit. med. J., (1977), **2**, 232. 3. Practitioner, (1976), **216**, 455. 4. £1.30 for 15 tablets. (Basic NHS). Price correct at time of going to press. April 1978.

Talpen* (talampicillin) is a product of British research from




Beecham Research Laboratories, Brentford, England. A branch of Beecham Group Limited. *Regd.

PL 0038/0209

BRL 1020

Trandate alone...

(labetalol)



THE FIRST ALPHA-BETA-BLOCKER Right in principle - working in practice

The mode of action of Trandate (labetalol) is different from that of any other antihypertensive agent currently available. Trandate works primarily by lowering peripheral resistance – the alpha-blocking effect – thereby correcting the basic pathophysiological defect. Unlike earlier alpha-blockers and direct acting vasodilators, reflexly moderated increases in heart rate are prevented by Trandate's beta-blocking action. But in contrast with simple beta-blocking drugs, the cardiac output is not reduced at rest and after moderate exercise¹. This means that the circulation is closer to normal and blood flow to the extremities and to vital organs, including the kidney, is satisfactorily maintained. Unlike diuretics, Trandate does not disturb fluid and mineral balance. And in contrast with the centrally-acting antihypertensives, sedation and lethargy are not features of Trandate therapy.

Trandate has now been generally available for the treatment of hypertension for well over a year and clinical experience to date reveals a clear picture of high efficacy and relative lack of side effects.

TRANDATE TABLETS PRODUCT INFORMATION

PRESENTATION AND BASIC NHS COST

Trandate Tablets 100mg or 200mg each contain 100 or 200mg labetalol hydrochloride. Basic NHS cost of 50 Tablets 100mg is £3.44 and of 50 Tablets 200mg is £4.88. Also available in containers of 250.

INDICATIONS

Trandate Tablets are indicated for the treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

DOSAGE AND ADMINISTRATION (ADULTS)

The recommended starting dose for all patients is 100mg three times a day after meals. A satisfactory reduction in blood pressure is achieved at this dose level in some patients, especially those already on diuretic therapy, but higher doses are often necessary. If the fall in blood pressure achieved is less than optimal, weekly or two-weekly dosage increases are advised, the first being to 200mg t.d.s.p.c. and then, if necessary, to 300mg t.d.s.p.c. The majority of patients will be controlled with dosages less than 1200mg per day but severe cases may require up to 2400mg daily and in exceptional cases doses greater than this have been used.

It is important to increase the dosage of Trandate gradually in order to avoid side effects. Trandate Tablets should be taken after food to avoid the possibility of gastric irritation. Once stabilised on an optimum dosage, where desirable, treatment can be changed to a twice daily regime.

Hypertension is usually controlled by Trandate alone. Diuretic therapy is not usually necessary in patients receiving Trandate Tablets, but may be introduced or continued if required. Diuretics usually increase the antihypertensive action of Trandate.

If Trandate Tablets are prescribed together with another antihypertensive drug, such as methyl dopa or clonidine, an additive effect may be expected in patients who are responsive to both drugs. When transferring patients from other drugs Trandate Tablets should be introduced as recommended above and the dosage of the existing therapy progressively decreased.

PRECAUTIONS

There are no known contra-indications to the use of Trandate Tablets.

Heart failure should be controlled with digitalis and diuretic therapy before treatment is initiated. Trandate should not normally be given to patients with digitalis-resistant heart failure or atrio-ventricular block.

Caution must be observed if Trandate is used to treat asthmatic patients or individuals prone to bronchospasm. Any resultant bronchospasm may be controlled by an inhaled selectively-acting bronchodilator such as salbutamol; the required dose may be greater than the normal anti-asthmatic dose. If further treatment is required, intravenous atropine 1mg should be given.

It is not necessary to discontinue Trandate Tablets in patients requiring anaesthesia but they should be given intravenous atropine prior to induction; the effect of halothane on blood pressure may be enhanced by Trandate.

Unnecessary administration of drugs during the first trimester of pregnancy is undesirable.

mild, moderate and severe



Trandate is a unique profile in hypertension treatment. It is a unique profile in patient compliance.

- For the newly-diagnosed hypertensive
- When control is inadequate on existing therapy
- When side effects are causing problems
- To replace complicated multi-drug regimens

References

1. Raftery, E.B., *Mod. Med.*, 1978, 23, 9.


2. Breckenridge, A.M. et al, 1977, *Brit. J. clin. Pharmac.*, 4, 388.

3. Material on file Allen & Hanburys Research Ltd.

Effect of Trandate on mild, moderate and severe hypertension in General Practice³


Before treatment

Percentage of total patients (n = 1980)



After 4 weeks treatment with Trandate alone up to 600mg daily

Percentage of total patients (n = 1980)



SIDE EFFECTS

Trandate is usually well tolerated.

Symptoms of postural hypotension may occur if the initial dosage is too high or if the dose is increased too rapidly but are uncommon, except at very high doses, if the drug is used as recommended. Patients with difficulties at first, usually tolerate the drug well after a few weeks' treatment.

Nasal stuffiness, vivid dreams and failure of ejaculation have been reported in a few patients. Epigastric pain has occurred in some individuals on high doses of the drug. Headache, nausea, lethargy, tiredness and cramp have also been reported but are usually transient and disappear after a week or so. Seldom has it been necessary to discontinue treatment with Trandate.

PRODUCT LICENCE Nos.

Trandate Tablets 100mg 0045/0106

Trandate Tablets 200mg 0045/0107

Trandate is also available as Trandate Injection for intravenous use in hospitalised patients.

Further information is available on request.

Trandate is a trade mark of the product licence holder
ALLEN & HANBURY LTD LONDON E2 6LA



TRANDATE
a unique
profile in
hypertension



One of a series of Hibernating animals: the Dormouse (*Myoxus avellanarius*) hibernates September to April

For safe, natural, undisturbed sleep...

REM NOS

Nitrazepam/DDSA

Now available in 2 strengths from DDSA only

Remnos brand of Nitrazepam is now available as tablets 5mg and 10mg

Patient convenience


Many patients require 2x5mg tablets at night. Now one tablet of Remnos 10mg fulfills this need

Prescribing convenience


The distinctive yellow colour of tablets Remnos 10mg clearly distinguishes this dosage form from tablets Remnos 5mg thus avoiding the likelihood of confusion

Cost saving

1x100 Remnos 10mg tablets costs 10% less than 2x100 Remnos 5mg



Remnos 5mg tablets



Remnos 10mg tablets

food ...or thought

A sensible diet is an important factor in the management of gastro-intestinal complaints. Sensible medication is another. This is where Libraxin comes in.

Psychological factors are considered important in the management of many illnesses, but perhaps no more so than in gastro-intestinal complaints. In some, for example irritable colon, the emotions

are thought to have an aetiological role; in others, for example peptic ulcer, they may influence the clinical manifestations and the subsequent treatment of the patient.

Libraxin helps to improve the prognosis by altering the patient's outlook whilst at the same time relieving the physical symptoms by decreasing hypermotility and hypersecretion in the gut.

LIBRAXIN

For the treatment of a wide range of gastro-intestinal disorders with an emotional component, including nervous dyspepsia, peptic ulcer, cardiospasm, pylorospasm, nervous or irritable colon.

Libraxin is the trade mark for pharmaceutical preparations containing chlordiazepoxide and clidinium bromide.

References

Cromwell, H.A., *Med Jms* (NY), 1968, 96, 933
Head, H.B., and Hammond, J.B., *Amer. J. dig. Dis.*, 1968, 13, 540
McHardy, G., *et al.*, *Gastroenterology*, 1968, 54, 508

Full prescribing information is available



Roche Products Limited
PO Box 2LE, 15 Manchester Square, London W1A 2LE



UPDATE BOOKS

Medical Aid at Accidents

'This book covers the basic knowledge required for most aspects of emergency care and rescue organisation by a series of short, relevant, and beautifully illustrated chapters. . . . This is a significant contribution to the discipline of emergency care and can be recommended for use internationally.' The Lancet

Roger Snook, 1974, 235 figures, 136 pp, hardback, price £5.75 + 70p p&p.

Rehabilitation Today

'Every medical practitioner, every medical student (and every dean) should . . . have access to a copy of this book. . . . Its use as a source of reference should become second nature.' British Medical Journal

Stephen Mattingly (Ed.), 1977, 216 figures, 189 pp, paperback, ISBN 0 906141 00 1, price £4.95 + 70p p&p.

Dermatology

'The first edition of this book was a landmark in medical publishing. The second edition contains 506 new colour illustrations, together with a comprehensive text. It will have immediate practical value to general practitioners, physicians, dermatologists, students and all others with an interest in this field.'

Lionel Fry, 2nd edition, 1978, 506 figures, 168 pp, hardback, ISBN 0 906141 02 8, price £6.50 + 75p p&p.

Neonatal Medicine

'An up-to-date, down-to-earth text which makes clear to the occasional neonatologist, whether he or she be a general practitioner, a paediatrician or obstetric resident, or a midwife, how common problems should be handled in the light of current knowledge.' Professor J. A. Davis, University of Manchester

Malcolm Chiswick, 1978, 113 figures, 112 pp, hardback, ISBN 0 906141 01 X, price £3.95 + 70p p&p.

Oral Disease

'A practical, profusely illustrated guide to diseases of the mouth, written specifically for a medical audience. It will contribute to the early recognition, prompt referral and treatment of such diseases and will be of great value to all doctors who look in the mouth, and to dentists and dental students.'

C. E. Renson (Ed.), 1978, 230 figures, 96 pp, hardback, ISBN 0 906141 04 4, price £3.95 + 70p p&p.

The following Update books are in preparation. Further details will be announced in this journal soon.

Immunisation

George Dick, July 1978, paperback, ISBN 0 906141 03 6, price £3.50 + 70p p&p.

Preventive Dentistry

Leon Silverstone, autumn 1978.

Interpreting the Electrocardiogram

James Fleming, autumn 1978.

ALL UPDATE BOOKS ARE AVAILABLE TO PERSONAL CALLERS AT OUR LONDON OFFICE OR BY POST. TO ORDER BY POST, COMPLETE THE ATTACHED FORM AND POST WITH YOUR REMITTANCE TO:

UPDATE PUBLICATIONS LIMITED

**33/34 ALFRED PLACE
LONDON WC1E 7DP**

These prices apply only until 31 December 1978.

ORDER FORM

	Number of copies required	Remittance enclosed
Medical Aid at Accidents	<input type="text"/>	<input type="text"/>
Rehabilitation Today.....	<input type="text"/>	<input type="text"/>
Dermatology	<input type="text"/>	<input type="text"/>
Oral Disease.....	<input type="text"/>	<input type="text"/>
Neonatal Medicine.....	<input type="text"/>	<input type="text"/>
Immunisation.....	<input type="text"/>	<input type="text"/>

Please type or print your name and address clearly in block capitals. Cheques or postal orders should be made payable to Update Publications Ltd and sent to the address given above. These books are only available by direct sale, cash with order.

NAME

ADDRESS

.....
.....

Money back guarantee. If you are dissatisfied with your book and return it to us in perfect condition within 28 days, your money will be refunded in full.

CO/9/78

CLASSIFIED ADVERTISEMENTS AND NOTICES

Classified advertisements are welcomed and should be sent to: Mr Mike Fulton, Advertisement Director, *The Journal of the Royal College of General Practitioners*, Update Publications Ltd., 33/34 Alfred Place, London WC1E 7DP. Copy must be received by 1st of the month preceding the month of issue to ensure inclusion. Every effort will be made to include advertisements received after this date but publication cannot be guaranteed and the advertisement may have to be held over to the following issue.

The charge for space in this section is £5.75 per single column centimetre, plus 25p if a box number is required. Fellows, members and associates of the Royal College of General Practitioners may claim a ten per cent reduction.

The inclusion of an advertisement in this Journal does not imply any recommendation and the Editor reserves the right to refuse any advertisement. All recruitment advertisements in this section are open to both male and female applicants.

Readers are asked to mention *The Journal of the Royal College of General Practitioners* when replying to all advertisements.

Australian Family Physician

Journal of the Royal Australian College of General Practitioners (Publishers).

Would you like to subscribe to an overseas Journal?

The Journal, which reports the activities of the College, contains much clinical material and information for general practitioners in all parts of the world. Readers will find authoritative articles on clinical problems, self assessment, education and research.

The Journal is published monthly, and distributed to all general practitioners in Australia as well as all final year medical students, and resident medical officers.

Subscription rate is: A. \$25 per annum.

Address all communications to:

**The Managing Editor,
Australian Family Physician,
4th Floor, 70 Jolimont St.,
Jolimont, Victoria, Australia 3002**

GLOUCESTERSHIRE GENERAL PRACTITIONER TRAINING SCHEME

Applications are invited for four Traineeships from Doctors wishing to commence vocational training for general practice in February 1979.

The scheme is arranged between the Cheltenham and the Gloucester Health District and the Area General Practice Advisory Committee. The scheme provides an excellent grounding in all aspects of hospital and general practice and is approved for the Membership Examination of the RCGP. The training programme is arranged as follows:

1. A four week attachment to a general practice commencing February 1979.
2. Four hospital attachments rotating at six monthly intervals:
 - a) SHO Accident and Emergency with Orthopaedics — Cheltenham
 - b) SHO General Medicine — Gloucester
 - c) SHO Paediatrics — Cheltenham
 - d) SHO Psychiatry — Gloucester.These posts will involve compulsory residence in the Hospital.
3. A final training period of 11 months in General Practice.

A half-day day release is held in the post-graduate medical centres at Cheltenham and Gloucester which the trainees are expected to attend.

Application forms and further details available from Mrs M. Pearson, Acting Senior Personnel Assistant, Cheltenham Health District, Cheltenham General Hospital, Sandford Road, Cheltenham. Tel. 0242 21344 Ext. 202.

Closing date for applications 18th September 1978.

GRANTS FOR CONVALESCENCE

We have money available for your patient who is a woman (single or married) who has or has had in the past a job of a broadly professional nature to pay for or towards the cost of convalescence which you certify she needs.

Please write or telephone for full information from:

**Andrew & Co.,
St Swithin's Square, Lincoln
Tel. No. 0522-32123**

TRAINEE VACANCY

Any trainee who comes to us for one year must risk being spoilt by the beauty of rural Wales. Three partners have equipped the practice and we find life both interesting and satisfying. Pleasant unfurnished accommodation is available and applicants can contact our present trainee.

The trainee vacancy begins on 1 October 1978 and applications and enquiries should be made to Dr J. E. Hughes, The Clinic, Llanfair Caereinion, Welshpool, Powys.

THE LONDON HOSPITAL,
WHITECHAPEL, E1 1BB
(City & East London AHA (T))

**THE EAST LONDON GENERAL
PRACTITIONER VOCATIONAL TRAINING
SCHEME IN CONJUNCTION WITH THE
LONDON HOSPITAL**

Applications are invited for the four posts in this scheme, starting on 1st February 1979. Each trainee will be invited to spend one month in general practice, two years rotating in posts at the London Hospital and finally one year in general practice. The hospital posts include Obstetrics and Gynaecology, Geriatrics, General Medicine, Paediatrics, Psychiatry and the Emergency and Accident Department. A half day release course is held at the East London Post-graduate Centre, Bethnal Green. Applicants will be welcome to visit the training practices.

Further details may be obtained from the Course Organiser, Dr R. M. Griffiths, 35 High Street South, East Ham, London E6 or from the Medical Staffing Officer, The London Hospital.

Applications (no forms provided), giving the names and addresses of two referees, should be received by 3rd November 1978 and addressed to the Medical Staffing Officer, The London Hospital.

THE NEW POLICE SURGEON

A practical guide to Clinical Forensic Medicine

Foreword by Sir Robert Mark

560 pages

89 illustrations

This book, which is sponsored by the W. G. Johnston Trust, has been hailed as an excellent publication and the first major work of its kind. It's appeal is not restricted to police surgeons only but will be invaluable to all practitioners of clinical forensic medicine, candidates for the DMJ parts I and II, forensic general pathologists, casualty officers, and general medical practitioners.

Copies should be obtained for the libraries of post-graduate medical centres, and for pathology, paediatric, casualty, and other hospital departments.

Please send me _____ copy/copies of The New Police Surgeon, price £18 plus £1 p & p. I enclose a cheque/postal order made payable to The W. G. Johnston Trust for £_____

Name _____

Address _____

Block
Capitals
Please

Please send completed application form and remittance to:

**Dr J. E. Hilton, St Andrews House, Witton,
Norwich NR13 5DT.**

**JOURNAL OF THE ROYAL COLLEGE OF
PHYSICIANS OF LONDON**

This Journal is concerned with the integration of scientific disciplines in the practice of medicine and, by providing a wide ranging commentary on the growing points of medicine, is an essential complement to the specialized journals.

CONTENTS OF VOLUME 12, NO. 5

R. M. Murray	The health of doctors: a review.
S. Sullivan, E. B. D. Hamilton and R. S. Williams	Rheumatoid arthritis and liver involvement.
E. C. Huskisson, A. W. F. Lettin and D. L. Woolf	Modern management of rheumatoid arthritis.
Sir Geoffrey Keynes	Notes for the Life of William Harvey.
J. P. Sparks	Recent experience of influenza.
E. N. Wardle	Understanding ferments.
Editor:	A. Stuart Mason, MD, FRCGP
Publication:	Published quarterly in January, April, July and October.
All inquiries to Editorial Office:	Royal College of Physicians of London, 11 St Andrew's Place, Regent's Park, London NW1 4LE.

INDEX TO ADVERTISERS

	page		page
Allen and Hanburys Ltd <i>Trandate</i>	536/537	Duncan Flockhart & Co Ltd <i>Fluvirin</i> <i>Paramol 118</i>	523 535
Beecham Research <i>Talpen</i>	524	Leo Laboratories Ltd <i>Fucidin Topical</i> outside back cover	
Bencard Ltd <i>Amoxil</i>	576	Roche Products Ltd <i>Libraxine</i>	546
DDSA Pharmaceuticals Ltd <i>Remnos</i>	542	Schering Chemicals Ltd <i>Cyclo Prognova</i> inside front cover	
Dales Pharmaceuticals Ltd <i>Inolaxine</i>	530	Smith Kline & French <i>Tagamet</i>	514
		Update Publications Ltd	552

Somebody has prescribed
~~20~~ 20,000,000
tubes of **fucidin**...



is it
YOU?

In boils, dirty wounds, impetigo and most other soft tissue bacterial infections- Fucidin works.

Topical Fucidin is available as Fucidin Gel, Fucidin H Gel, Fucidin H Ointment, Fucidin Tulle and Caviject... and of course

fucidin* ointment

Full prescribing information available from



Leo Laboratories Limited,
Hayes Gate House, Hayes, Middx.

*Fucidin is a trade mark for sodium fusidate.

Topical Fucidin 2% Fucidin, also available with 1% hydrocortisone. **Indications** Gram-positive skin infections. Hydrocortisone preparations for inflammatory dermatoses. **Contra Indications/Precautions** Infections due to non-susceptible organisms. Fucidin hypersensitivity. Avoid extensive use of hydrocortisone in pregnancy and infants. Do not use in or near eyes. **Adverse Reactions** Occasional hypersensitivity reactions.